We’ve talked about clinical trial readiness repeatedly in this space. Probably we all, as an industry, have a good sense of what that means — or what it used to mean. The definition has acquired a whole new dimension in recent days. For example, this post was originally planned to be about a theoretical subset of sites
We recently talked with Atlantic Research Group (ARG) executives Shay Brill, VP at ARG, and Erin Farris, Senior Director Project Management, about clinical trial operations, how they are changing, and how they are likely to change. We wanted to share this excerpt from the conversation:
What are your predictions for how clinical operations will work— or should work—in the future?
Over the last year, we’ve been utilizing data analytics more and
We recently talked with Adam Kinsey, Executive Director, Clinical Sciences and Study Management—Oncology at Merck, about staffing clinical trial operations as part of our new interview series Conversations in Clinical Trial Readiness, by ArcheMedX.
We wanted to share this excerpt from the conversation with Adam:
When you are working on the